Trials / Unknown
UnknownNCT02012140
Pharmacokinetics and Pharmacodynamics of Ticagrelor in Patients With Stable Angina, NSTEMI and STEMI Undergoing PCI
- Status
- Unknown
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 200 (estimated)
- Sponsor
- LifeBridge Health · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Ticagrelor therapy has been shown to reduce the rates of cardiovascular events and all-cause mortality compared to clopidogrel therapy in patients with acute coronary syndromes (ACS). The benefit of this study would be to demonstrate that ticagrelor therapy is associated with equivalent platelet inhibition irrespective of the disease status in patients undergoing PCI.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ticagrelor |
Timeline
- Start date
- 2014-01-01
- Primary completion
- 2015-01-01
- First posted
- 2013-12-16
- Last updated
- 2013-12-16
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02012140. Inclusion in this directory is not an endorsement.